Skip to main content
Dr. Lal Pathlabs Limited logo

Dr. Lal Pathlabs Limited — Investor Relations & Filings

Ticker · LALPATHLAB ISIN · INE600L01024 LEI · 984500E8E9CY102B9718 BSE.NS Human health and social work activities
Open in API
Filings indexed 1,098 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country IN India
Listing BSE.NS LALPATHLAB

About Dr. Lal Pathlabs Limited

https://www.lalpathlabs.com/

Dr. Lal Pathlabs Limited is a provider of diagnostic and related healthcare tests and services. The company offers a comprehensive range of clinical laboratory tests and profiles used for prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. Its service portfolio encompasses pathology, including biochemistry, hematology, clinical pathology, histopathology, and molecular diagnostics, as well as radiology services such as X-ray, ultrasound, and CT scans. The organization operates an extensive network of laboratories, patient service centers, and pick-up points, utilizing advanced automated systems and standardized processes. Key offerings include specialized wellness packages and home sample collection. The company maintains high quality standards through international and national accreditations, serving a diverse patient base and healthcare providers with a focus on accuracy and timely reporting.

Recent filings

Filing Released Lang Actions
Appointment
Regulatory Filings
2026-04-30 English
Appointment
Annual Report Classification · 95% confidence The document is a detailed announcement from Dr. Lal PathLabs dated April 30, 2026, reporting the outcome of a Board Meeting. It includes approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, along with the auditors' report. The document also covers multiple corporate actions such as dividend recommendation, acquisition, incorporation of a subsidiary, appointments of directors and senior management personnel, re-appointment of auditors, employee stock option allotment, and convening of the Annual General Meeting. The presence of the full auditor's report on the consolidated financial results and detailed financial data indicates this is not merely an announcement but contains substantive financial information. The document is comprehensive and includes actual financial results and audit opinions, which aligns with the characteristics of an Annual Report (10-K equivalent). Although it is titled as an outcome of a board meeting, the inclusion of audited financial results and auditor's report for the full fiscal year ending March 31, 2026, supports classification as an Annual Report rather than a simple announcement or regulatory filing. Therefore, the appropriate classification is Annual Report (10-K).
2026-04-30 English
ESOP/ESOS/ESPS
Annual Report Classification · 95% confidence The document is a detailed announcement from Dr Lal PathLabs dated April 30, 2026, reporting the outcome of a Board Meeting. It includes approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, accompanied by auditors' reports with unmodified opinions. The document also covers final dividend recommendation, acquisition of a subsidiary, incorporation of a wholly owned subsidiary, appointments and re-appointments of directors and senior management personnel, re-appointment of auditors, allotment of shares under an employee stock option plan, and convening of the 32nd Annual General Meeting. The presence of audited financial results for the full fiscal year, auditor's detailed opinion, and comprehensive financial and corporate governance information indicates this is an Annual Report or equivalent comprehensive financial disclosure. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K).
2026-04-30 English
Record Date
Annual Report Classification · 95% confidence The document is a detailed announcement from Dr. Lal PathLabs dated April 30, 2026, reporting the outcome of a Board Meeting. It includes approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, along with the auditors' report. The document also covers multiple corporate actions such as dividend recommendation, acquisition, incorporation of a subsidiary, appointments of directors and senior management, auditor re-appointments, employee stock option allotment, and AGM convening. The presence of the full auditor's report on the consolidated financial results and detailed financial data indicates this is not merely an announcement but contains substantive financial information. The document is comprehensive and exceeds 15,000 characters, indicating it is a full report rather than a brief announcement. The key focus on audited financial results for the full fiscal year ending March 31, 2026, aligns with the definition of an Annual Report (10-K). Therefore, the document should be classified as an Annual Report (10-K).
2026-04-30 English
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a detailed announcement from Dr. Lal PathLabs dated April 30, 2026, reporting the outcome of a Board Meeting. It includes multiple items such as approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, recommendation of final dividend, acquisition of a subsidiary, incorporation of a wholly owned subsidiary, appointments and re-appointments of directors and senior management personnel, re-appointment of auditors, allotment of shares under an employee stock option plan, and convening of the 32nd Annual General Meeting. The document also includes an independent auditor's report on the audit of annual consolidated financial results and review of quarterly financial results, with detailed auditor opinions and responsibilities. The presence of audited financial results for the full fiscal year ending March 31, 2026, along with auditor's report and detailed financial information, indicates this is the official annual report covering company activity and full financial performance. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K).
2026-04-30 English
Dividend
Annual Report Classification · 95% confidence The document is a detailed announcement from Dr. Lal PathLabs dated April 30, 2026, reporting the outcome of a Board Meeting. It includes multiple items such as approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, recommendation of final dividend, acquisition of a subsidiary, incorporation of a wholly owned subsidiary, appointments and re-appointments of directors and senior management personnel, re-appointment of auditors, allotment of shares under an employee stock option plan, and convening of the 32nd Annual General Meeting. The document also includes an independent auditor's report on the audit of annual consolidated financial results and review of quarterly financial results, with detailed auditor opinions and responsibilities. The presence of audited financial results for the full fiscal year ending March 31, 2026, along with auditor's report and detailed financial information, indicates this is a full annual report of financial performance. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K).
2026-04-30 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.